Q4 revenue will be 12% royalty (US$250-500 million), Neuren was guiding slightly higher revenue for Q4 (US$92+million) which with the current favourable exchange rate will beat guidance of AUD$16-18 million ever so slightly.
The big difference will be the ~AUD $10 million increase from favourable exchange rate on the US$50 million PRV voucher sale proceeds and the US$50 million milestone payment.
So CY2024 total somewhere between AUD $227-229 million beating guidance of AUD$216-218 million. I'm lousy at maths so dismantle at your leisure haha
- Forums
- ASX - By Stock
- Ann: Trofinetide marketing application submitted in Europe
NEU
neuren pharmaceuticals limited
Add to My Watchlist
5.52%
!
$14.05

Q4 revenue will be 12% royalty (US$250-500 million), Neuren was...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.05 |
Change
0.735(5.52%) |
Mkt cap ! $1.756B |
Open | High | Low | Value | Volume |
$13.50 | $14.21 | $12.96 | $6.233M | 452.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 31 | $14.04 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.05 | 112 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 155 | 14.130 |
4 | 384 | 14.120 |
3 | 390 | 14.110 |
3 | 553 | 14.100 |
4 | 1284 | 14.090 |
Price($) | Vol. | No. |
---|---|---|
14.150 | 398 | 5 |
14.160 | 265 | 2 |
14.170 | 1212 | 5 |
14.180 | 1398 | 9 |
14.190 | 1203 | 6 |
Last trade - 14.02pm 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online